



VOLUME 03 ISSUE 01 (2024)

AMERICAN JOURNAL OF  
**LIFE SCIENCE  
AND INNOVATION**  
(AJLSI)

ISSN: 2833-1397 (ONLINE)

PUBLISHED BY  
E-PALLI PUBLISHERS, DELAWARE, USA

## Revolutionizing Pediatric Dermatology: Dupilumab's Impact on Atopic Dermatitis in Kids

Eiman Hamza Ahmed Elsayed<sup>1\*</sup>, Rabab Elsayed Ali Hassan Khater<sup>2</sup>

### Article Information

**Received:** May 01, 2024

**Accepted:** May 31, 2024

**Published:** June 04, 2024

### Keywords

*Atopic Dermatitis, Pediatrics, Dupilumab, Immunosuppressants, Monoclonal antibodies, Corticosteroids*

### ABSTRACT

Eczema, or atopic dermatitis, is a common, non-communicable, immune-mediated, inflammatory skin illness mainly affecting children. It is a chronic condition. It causes mental health problems like anxiety, sadness, anxiety, depression, hyperactivity, and obesity. It is the first skin ailment and the fifteenth non-fatal disease. The purpose of the present research study was to evaluate the Safety and Effectiveness of biological treatment for atopic dermatitis using monoclonal antibodies against non-biological treatment, including antibiotics, immunosuppressants, demards, histamine antagonists and corticosteroids. Patient information was gathered from FDA-approved clinical trials. The comparative analysis found that Biological therapies like Dupilumab, Omalizumab, and Ustekinumab improve symptoms and disease control in atopic dermatitis. Non-biological treatments may not be as effective. Early antibiotic exposure can increase infection vulnerability. Mild eczema infections require biological agents. Topical corticosteroids can be combined with Dupilumab for effective treatment of atopic dermatitis. Studies show that Dupilumab improves symptoms and quality of life, making it a better option than a placebo. FDA recommends using biological agents over immunosuppressants in paediatrics for improved immune results. FDA clinical trials showed that dupilumab is a safe and effective treatment for children with moderate-to-severe atopic dermatitis, reducing disease severity and improving quality of life in young AD patients.

### INTRODUCTION

Atopic dermatitis (AD), known as Eczema, is a common, chronic, non-communicable, immune-mediated inflammatory skin condition that mostly affects children. It ranks first among all skin illnesses and 15th among non-fatal diseases (Rusiñol & Puig, 2024). It typically manifests within the first six months of life. It harms general health and is linked to a higher occurrence of mental health conditions and symptoms, including anxiety, depression, hyperactivity, sleep problems, asthma, hay fever, cardiovascular disease, stroke, and obesity (Chovatiya & Silverberg, 2019; Nicholas *et al.*, 2022; Xu *et al.*, 2019).


It is caused by changes in the skin microbiota immune system hyperactivity, sensitivity to immunoglobulin E, neuro-inflammation (Mandlik & Mandlik, 2021), environmental variables, and hereditary predisposition. (Grobe *et al.*, 2019; Mehta & Fulmali, 2022). The intricate interactions between itch, inflammation, and barrier failure play a crucial role in this condition's onset, progression, and chronicity, even though the pathophysiological mechanisms are yet unknown.

Skin inflammation that is aggravated by flaggrin abnormalities, intercellular lipids, and tight junctions is the hallmark of type 2 immune deviation. These abnormalities lead to barrier disruption in the skin, producing thymic stromal lymphopoietin, interleukin (IL)-25, and IL-33.

Subsequently, this inflammation intensifies the breakdown of the epidermal barrier by suppressing

flaggrin expression in keratinocytes. Moreover, various pruritogens and itch mediators generated during this inflammatory process can directly affect sensory nerves and induce itching (Kim *et al.*, 2019; Nakahara *et al.*, 2021). While in some children, food allergies are closely associated with AD, 30% of these children experience symptoms such as rash, itching, leaking, and dry, cracked skin. Smaller kids show intolerance to some foods.

Red, weepy, crusty, itchy, and flaky skin patches that typically form in oval or circular forms are its defining feature (Rusiñol & Puig, 2024). Age-related symptom variations include red rash in infants, thickened rash in children, and scaly rash in teens and adults. Common



**Figure 1:** Conditions related to atopic dermatitis

<sup>1</sup> Pediatric Specialist in UAE

<sup>2</sup> Dermatology Specialist in UAE

\* Corresponding author's e-mail: [dr\\_ch2412@yahoo.com](mailto:dr_ch2412@yahoo.com)

features include extra skin folds and darkening (Frazier & Bhardwaj, 2020; Soares *et al.*, 2024).

For patients with moderate to severe types of atopic dermatitis (AD), biological therapies are very important. These therapies concentrate on particular molecules involved in the inflammatory and immunological responses typical of AD. Compared to more conventional treatments like corticosteroids or immunosuppressive medications, biological therapies like monoclonal antibodies like Dupilumab and Tralokinumab provide a more tailored approach by concentrating on particular molecular targets (Deleanu & Nedelea, 2019).

New insights into the immunopathology of AD have made it possible to identify therapeutic molecular targets for innovative biological therapies. By modifying the immune response and inflammatory pathways, these treatments; including “IL-4/IL-13” inhibitors, JAK inhibitors, and “IL-13 inhibitors” have demonstrated notable success in treating AD. Furthermore, the FDA has approved biologics like Dupilumab for treating moderate-to-severe AD, demonstrating their efficacy in enhancing patients’ quality of life and symptom relief (Zhou *et al.*, 2021).

It provides a more focused and targeted approach. Research has indicated that biological treatments are a useful means of alleviating symptoms. Furthermore, biologics have demonstrated a quick start of action, offering immediate relief to patients who have not responded well to traditional therapy. Clinical trials and real-world applications have provided strong evidence for the Safety and Effectiveness of biological therapy (Caffarelli *et al.*, 2023; Montes-Torres *et al.*, 2015).

The present research paper aimed to evaluate and compare the efficacy, optimal dosage, and frequency of administration of biological treatment such as monoclonal antibody Dupilumab with standard treatment options, including antibiotics, corticosteroids, Immunosuppressants such as cyclosporine, mycophenolate, tacrolimus, and azathioprine, histamines, and Demards like Methotrexate in the management of atopic dermatitis in pediatric patients.

### Methods and Clinical Trials

The research study on “Revolutionizing Pediatric Dermatology: Dupilumab’s Impact on Atopic Dermatitis in Kids” was conducted by employing the approved clinical trials studies of “United States-Food & Drug Administration (FDA)” among individuals of different ages, ethnicity, genders and health status.

### Biological Treatment Options

#### Efficiency of Biological Treatment

Systemic non-biological therapies, such as oral corticosteroids, cyclosporine, Methotrexate, azathioprine, and mycophenolic acid, effectively manage moderate to severe atopic dermatitis (Paolino *et al.*, 2023). Non-biological systemic therapy for atopic dermatitis may not be as effective at controlling symptoms and preventing

exacerbations as biological treatments are (Ferrucci *et al.*, 2023).

Meanwhile, biological therapies, including Dupilumab, Omalizumab, and Ustekinumab, offer a more targeted approach focusing on molecules linked to the immune response and inflammatory processes in AD. These biologics have shown a significant improvement in symptoms and quality of life for those with moderate to severe AD (Chu *et al.*, 2023) and disease control by targeting key pathways involved in AD pathogenesis, such as Th2, Th22, Th17/IL-23, and IgE.

### Monoclonal Antibody Dupilumab

Dupilumab obstructs the signalling pathways for interleukin 13 (IL-13) and 4 (IL-4). Attaching to the alpha subunit of the interleukin-4 receptor (IL-4R $\alpha$ ), this method of action functions as a receptor antagonist. Dupilumab specifically targets two important cytokines involved in asthma and atopic dermatitis inflammation: “IL-4 and IL-13” intracellular signalling. The simultaneous inhibition of “IL-4 and IL-13” signaling enhances skin barrier function, reduces type 2 inflammation, reduces itching, and improves skin lesions in people with atopic dermatitis. (Kraft & Worm, 2017).

Dupilumab significantly enhances clinical scores and symptoms in children with severe atopic dermatitis aged 6-11 years, improving their quality of life and smoother skin (Berna-Rico *et al.*, 2023; Cork *et al.*, 2024).

The recommended dosages and frequency of dupilumab for children with atopic dermatitis are weight-based and range from 200 mg to 300 mg for children weighing 15 to 30 kg, 30 to 40 kg, and 40 kg or more (Berna-Rico *et al.*, 2023; Cork *et al.*, 2024; Kamal *et al.*, 2021).

### Comparison with Other Treatment Modalities

#### Antibiotics for Atopic Dermatitis

Since secondary skin infections frequently arise in AD patients, antibiotics, including cephalexin, clindamycin, doxycycline, azithromycin and amoxicillin/clavulanic acid, are frequently used to manage AD.

In eczematous lesions of atopic patients, Staphylococcus aureus colonization is common. It releases superantigens and exotoxins that prolong inflammatory reactions and worsen symptoms. Patients with AD are often offered topical antibiotics such as gentamicin, fusidic acid, and mupirocin for mild to moderate secondary infections (Neri, 2015).

#### Cephalexin

Is a first-generation cephalosporin used to treat Staphylococcus aureus-related skin infections in atopic dermatitis, particularly in those with colonized Staphylococcus aureus. Its bactericidal activity supports its use in treating atopic dermatitis, prophylaxis, and minor procedures (Class *et al.*, 2022; Rist *et al.*, 2002).

#### Clindamycin

A Lincosamide antibiotic, is used to treat severe skin and

soft tissue infections caused by *Staphylococcus aureus*. It works well against aerobic and anaerobic bacteria, especially in those with *S. aureus* colonization due to atopic dermatitis (Coskey, 1978; Mose *et al.*, 2022).

### Doxycycline

A tetracycline antibiotic doxycycline, has been investigated for treating atopic dermatitis (AD). Doxycycline may be able to treat AD since research indicates that it may include anti-inflammatory qualities and antibacterial benefits. Doxycycline may have a role in regulating the immune response in allergy disorders such as AD.

Its use has been widely demonstrated to reduce mast cell histamine release and asthmatic patients' levels of immunoglobulin E (IgE) for skin disorders such as rosacea, acne, and perioral dermatitis (Bohannon *et al.*, 2020; Hulme, 2023); It also functions by destabilizing nitric oxide synthase (NOS), which can reduce inflammation and improve symptoms of atopic dermatitis by increasing degradation. It is frequently used to treat skin conditions such perioral dermatitis, acne, and rosacea. (Bohannon *et al.*, 2020).

### Effectiveness and Limitations

Children who were exposed to antibiotics in their early years had a higher chance of acquiring adverse events. Irrational and direct use of broad-spectrum antibiotics increases susceptibility to infections and resistance rates, potentially leading to fatal diseases.

The relative efficacy of antibiotics and biological treatment for pediatric atopic dermatitis depends on the particular circumstances and degree of the ailment. Although they have a limited effect in treating the underlying inflammation of Atopic dermatitis, antibiotics are frequently used to treat infections that may worsen the symptoms of atopic dermatitis. According to research, antibiotics may not significantly help children with minor eczema infections, and they may even increase skin sensitivity and resistance (Choi *et al.*, 2020; Li *et al.*, 2021; Mubanga *et al.*, 2021).

### Corticosteroids in Atopic Dermatitis Management

Depending on the severity of the ailment, different dosages and potencies of corticosteroids, such as Hydrocortisone, fluticasone, betamethasone valerate, and tacrolimus, are frequently given to treat atopic dermatitis (Drucker *et al.*, 2018; Stacey & McEleney, 2021).

### Hydrocortisone

Hydrocortisone is frequently used for the treatment of atopic dermatitis in a variety of dosages and formulations. Hydrocortisone comes in various formulations for atopic dermatitis, with concentrations ranging from 0.1% to 2.5%. These formulations include creams, lotions, gels, solutions, and ointments.

Lower potency hydrocortisone formulations “(class VI or VII), such as 1% cream” or ointment, are usually used for infants and children with atopic dermatitis. These

formulations are administered twice a day to reduce inflammation and itch.

Low-potency steroids should be used for maintenance in cases of mild atopic dermatitis after intermediate-potency steroids (class III, IV, and V) are taken for short periods to control flare-ups in severe atopic dermatitis cases in teenagers (Haeck *et al.*, 2011), while their excessive strength may result in negative side effects such as folliculitis, dermatitis, acne, atrophy of the skin, itchiness, changes in pigmentation, and inhibition of the hypothalamic-pituitary-adrenal axis (Axon *et al.*, 2021).

### Fluticasone

A corticosteroid, is available in several formulations and doses ranging from 0.05% to 2.5%. It is used in atopic dermatitis to reduce inflammation and symptoms by suppressing the release of inflammatory mediators (Dhamija *et al.*, 2024).

On the other hand, a variety of negative side effects might occur, such as increased hair growth, dizziness, rash, itching, and redness of the treated area of skin. Hives, breathing difficulties, swelling of the lips, tongue, or throat, skin pain, tenderness, or swelling, wounds that do not heal, severe skin irritation, or signs of systemic absorption such as weight gain, thinning or discolored skin, increased body hair, nausea, diarrhoea, fatigue, mood swings, menstrual changes, and sexual changes, as well as severe headaches, confusion, muscle weakness, vision abnormalities, heart symptoms, or serious allergic reactions are examples of serious side effects that can occur. (Berth-Jones *et al.*, 2003; Harvey *et al.*, 2023).

### Betamethasone Valerate

0.1% twice daily for three to five days. The corticosteroid betamethasone can efficiently manage Children's eczema flare-ups, which enhances skin barrier function and reduces skin inflammatory responses (Subramanian *et al.*, 2018).

### Topical & Oral Corticosteroids Effectiveness in Comparison with Dupilumab-FDA

It has been shown that Dupilumab (Dupixent) can be used with or without topical corticosteroids in the treatment of disorders like atopic dermatitis based on the information from the sources that have been presented, including the FDA clinical trials and reviews on the drug. Dupilumab is a useful therapeutic option for moderate-to-severe atopic dermatitis since clinical trials have demonstrated that adding it to topical corticosteroids has significantly improved patient-reported symptoms and quality of life. According to a study, dupilumab is far more effective than a placebo in relieving the condition of individuals with atopic dermatitis when used in conjunction with topical corticosteroids.

These trial studies have demonstrated the advantages of using Dupilumab with topical corticosteroids, highlighting the drug's efficacy in treating atopic dermatitis and minimizing the need for corticosteroids

alone. Consequently, dupilumab combined with topical corticosteroids is a beneficial therapeutic strategy for diseases like atopic dermatitis, providing patients with better results and a higher quality of life, according to data from FDA clinical trials and reviews (FDA, 2017).

### **Immunosuppressant's**

#### **Cyclosporine**

A calcineurin inhibitor, targets T cells specifically, inhibiting the transcription of the interleukin 2 gene, modifying the immune response, and lowering inflammation in diseases such as atopic dermatitis, typically administered at a dose of "5 mg/kg/day" and available in multiple forms, including intravenous formulations, oral solutions, and gelatin capsules (Amber & Tabassum, 2020; Antti *et al.*, 2021; Megna *et al.*, 2017; Rajagopalan *et al.*, 2022).

#### **Mycophenolate**

Based on numerous investigations and clinical trials, Mycophenolate mofetil (MMF) has demonstrated promising outcomes in treating atopic dermatitis. Studies showed that MMF is useful in treating moderate to severe AD among individuals who did not respond to conventional treatments; there was a notable improvement in the severity of the illness. MMF significantly reduced the SCORAD index, a gauge of the severity of AD, within a few weeks of treatment; it may be a useful substitute for people with severe or refractory types of AD because of fewer risks of causing adverse effects than other long-term therapies for the disease (Phan & Smith, 2020).

#### **Azathioprine**

Immunosuppressive drugs like azathioprine prevent the manufacture of purines, which impacts lymphocytes and helps regulate the immune system in atopic dermatitis (AD) by lowering inflammation and managing symptoms. The recommended daily dose of azathioprine for AD is 1-2.5 mg/kg, with adjustments based on individual patient response and tolerance. It can cause myelosuppression, increased risk of infection, and gastrointestinal problems.

### **Safety profile & Clinical trials of Immunosuppressants in Comparison with Dupilumab**

According to the information provided by the sources, including the FDA approvals and clinical trials on the drug, Dupilumab, also known as Dupixent, has been the subject of substantial research spanning over "60 clinical trials" involving over "10,000" patients with various chronic conditions.

For the treatment of disorders such as asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis, Dupilumab, a completely human monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling has demonstrated noteworthy clinical advantages. Dupilumab's Effectiveness in lowering type 2 inflammation, a major factor in many illnesses, has been demonstrated by these trials.

Specifically, the FDA has approved Dupilumab for kids

with eosinophilic esophagitis aged one year and older, as well as kids with moderate-to-severe atopic dermatitis aged six months to five years. (FDA, 2019).

### **Demands (Disease-Modifying Anti-Rheumatic Drugs) Methotrexate**

Inhibits the immune system by inhibiting DNA synthesis and cell division by blocking dihydrofolate reductase. For AD, Methotrexate is administered at a starting dose of 10.3-2.6 mg/week, which can be changed according to the patient's tolerance and reaction. Weekly increases are possible, with maintenance dosages of about "11.7 mg" (Lee *et al.*, 2020; Shah *et al.*, 2018).

### **Comparison with Biological Agents Like Dupilumab on Based on Clinical Trials**

In individuals with moderate to severe atopic dermatitis, Dupilumab has been demonstrated to be more successful than Methotrexate in reducing symptoms and quality of life. This conclusion is based on FDA clinical trials and real-world analysis comparing the two medications.

When compared to Methotrexate, the trials showed that Dupilumab improved atopic dermatitis symptoms and signs more, and there were fewer side effects and treatment discontinuations. For treating atopic dermatitis, Dupilumab is therefore thought to be more effective and tolerable than Methotrexate, according to data from FDA clinical studies and real-world research (FDA, 2017).

### **Histamines in Atopic Dermatitis Treatment**

Histamine antagonists, which block H1 and H4 receptors, reduce inflammation, nervous irritability, and itching to treat the symptoms of atopic dermatitis (AD). Chronic dermatitis lesions lessen pruritus and inflammatory cytokines; in AD mice models, they have anti-inflammatory and anti-pruritic properties (Albrecht & Dittrich, 2015; Ohsawa & Hirasawa, 2014; Schaper-Gerhardt *et al.*, 2020).

### **Histamine Antagonist's Comparison with Dupilumab-FDA Clinical Trials**

According to FDA clinical trials, Dupilumab is superior to histamine antagonists in treating disorders like atopic dermatitis and chronic spontaneous urticaria. Atopic dermatitis patients with moderate-to-severe AD have shown notable improvements in their quality of life and a reduction in the severity of their condition after using Dupilumab, an interleukin-4 receptor alpha antagonist.

Dupilumab, on the other hand, may provide a more thorough treatment of the disease's underlying inflammatory processes than histamine antagonists, which target histamine receptors to relieve symptoms like pruritus. Dupilumab is a better therapy choice than histamine antagonists for disorders including atopic dermatitis and chronic spontaneous urticaria because of its demonstrated ability to relieve signs and symptoms of AD with a tolerable safety profile (Hon *et al.*, 2021; Clinical trials 2017).

### Tacrolimus as an Immunosuppressant

Atopic dermatitis (AD) has found a valuable new therapy option in tacrolimus, a macrolide calcineurin inhibitor. It achieves its therapeutic effects through immune response modulation and inhibition of inflammatory processes linked to AD progression. In the treatment of moderate to severe AD, topical tacrolimus has demonstrated efficacy and safety, providing a non-corticosteroid option. Research has shown that tacrolimus ointment (available in 0.03% and 0.1% concentrations) is more effective in treating AD than pimecrolimus and moderate corticosteroids. Tacrolimus works by attaching itself to particular T cell receptors, which raises intracellular calcium levels and inhibits the transcription of cytokines such as “IL-2, IL-4, and IL-5”. Clinical studies have demonstrated topical tacrolimus’s Effectiveness in lowering AD severity ratings and improving safety profiles with less systemic absorption (Martins *et al.*, 2015; Umar *et al.*, 2022).

### Safety Profile & Clinical Trials in Comparison with Dupilumab

Compared to tacrolimus, the FDA clinical trials have yielded strong evidence for the safety and Effectiveness of dupilumab in treating ailments such as atopic dermatitis. Atopic dermatitis patients with moderate-to-severe AD have shown notable improvements in their quality of life and a reduction in the severity of their condition after using Dupilumab, an interleukin-4 receptor alpha antagonist.

Dupilumab is a better therapy option than tacrolimus for AD patients due to its great efficacy in reducing symptoms and enhancing quality of life, as demonstrated by clinical trials. Dupilumab is a better therapy choice than tacrolimus because of its focused mechanism of action and excellent safety profile (FDA, 2019).

### Summary of FDA-approved Clinical Studies

According to FDA clinical trials, Dupilumab has proven to be a highly effective and safe treatment for moderate-to-severe atopic dermatitis in children. In children with atopic dermatitis, aged “6 to 11 years”, who are not sufficiently managed by traditional therapy such as topical corticosteroids and emollients, these trials have assessed the real-world Effectiveness of dupilumab. Research has indicated that Dupilumab significantly improves overall quality of life, pruritus, sleep quality, and disease severity in young AD patients.

More specifically, at week sixteen of treatment, a large percentage of patients showed statistically significant improvements in the “Children’s Dermatology Life Quality Index (c-DLQI), Sleep NRS (S-NRS), Pruritus Numerical Rating Scale (P-NRS), and Eczema Area Severity Index (EASI) scores”. Based on these results, young patients with moderate-to-severe atopic dermatitis can benefit from using dupilumab as a treatment option. It is a viable therapeutic alternative beyond topical medications (FDA, 2019; Kamphuis *et al.*, 2022; Napolitano *et al.*, 2022).

### DISCUSSION

Eczema, or atopic dermatitis, is a chronic, non-communicable, inflammatory skin ailment mainly affecting children. It ranks first among skin conditions and fifteenth among non-fatal diseases, and it can cause mental health problems.

Biological therapies like Dupilumab, Omalizumab, and Ustekinumab target immune response and inflammatory processes in atopic dermatitis, improving symptoms, quality of life, and disease control. In contrast, Non-biological systemic therapy for atopic dermatitis may not be as effective in controlling symptoms and preventing exacerbations as biological treatments.

Early exposure to antibiotics can raise a child’s vulnerability to infections and resistance rates, which can result in life-threatening illnesses. The severity of the condition determines how well biological therapy and antibiotics work for pediatric atopic dermatitis. Dupilumab and other biological agents are suggested for children with mild eczema infections.

Topical corticosteroids can be used alone or with dupilumab, a medication used to treat atopic dermatitis. Clinical investigations demonstrate that augmenting corticosteroids with dupilumab greatly improves patients’ symptoms and quality of life. According to studies, dupilumab is a better treatment option for atopic dermatitis than a placebo, especially when used with topical corticosteroids.

According to FDA guidelines, biological agents are preferred in paediatrics over Immunosuppressant including cyclosporine, mycophenolate, azathioprine and antimetabolite methotrexate because of their Effectiveness in enhancing immune results rather than inhibiting the body’s immune system.

It was evident from FDA clinical trials that dupilumab is a safe and effective treatment for children with moderate-to-severe atopic dermatitis, ages 6 to 11. Studies reveal that in young AD patients, it considerably reduces the severity of the disease, pruritus, and general quality of life. In addition to conventional topical drugs, this treatment provides a good therapeutic alternative.

### Challenges and Considerations

#### Cost-effectiveness of Dupilumab in Comparison with Non-biological Treatments

The analysis revealed that although the costs of Dupilumab may be higher than those of non-biological treatments like topical medicines, it is related to more “Quality-Adjusted Life Years (QALYs)” and good cost-effectiveness ratios. It suggests that compared to more affordable standard treatments like moisturizers and emollients, Dupilumab adds value by significantly increasing health outcomes.

According to the research, dupilumab presents a novel and efficacious therapeutic option for patients with moderate-to-severe atopic dermatitis, particularly when the Effectiveness of conventional treatments is compromised. The severity of the ailment affects how

cost-effective Dupilumab is compared to non-biological treatments; more severe patients are likely to benefit more from Dupilumab in terms of better health and quality of life (Anderson III & Szefer, 2019; Sonya Kahn *et al.*, 2018).

### Adherence to Treatment Regimens in Pediatric Patients

In comparison to non-biological therapy, pediatric children with atopic dermatitis seem to adhere better to Dupilumab treatment regimens. Research has indicated that children with moderate-to-severe atopic dermatitis can experience improvements in disease severity, pruritus, sleep quality, and overall quality of life while using the completely human monoclonal antibody Dupilumab.

Based on actual data from clinical trials, Dupilumab significantly improves pediatric patients' scores on the "Eczema Area Severity Index (EASI), Pruritus Numerical Rating Scale (P-NRS), Sleep NRS (S-NRS), and Children's Dermatology Life Quality Index (c-DLQI)". Dupilumab is well-tolerated and efficacious in juvenile populations, as evidenced by the high percentage of patients achieving "EASI75" and the significant mean percentage reduction in P-NRS, S-NRS, and c-DLQI scores (Napolitano *et al.*, 2022; Papp *et al.*, 2021).

### CONCLUSION

#### Potential Advancements in Biological Therapies for Atopic Dermatitis

Targeted biological therapy dupilumab addresses treatment resistance and lowers the likelihood of relapse in patients with atopic dermatitis, improving treatment results and quality of life. This development in biological treatments is immensely beneficial in treating chronic inflammatory diseases like atopic dermatitis.

#### Importance of Personalized Treatment Approaches

Optimizing results for children with disorders such as atopic dermatitis requires the use of personalized therapy techniques utilizing monoclonal antibodies, such as Dupilumab.

Personalized treatment is a helpful therapeutic option for inadequately controlled atopic dermatitis, as studies in children aged 6-11 reveal significant improvements in disease severity, pruritus, sleep quality, and quality of life.

### RECOMMENDATIONS

➤ Real-world data on Dupilumab's Effectiveness in diverse pediatric populations is needed to validate clinical trials and provide insights into its wider patient cohorts.

➤ Examine the long-term safety and efficacy of dupilumab in treating pediatric patients with atopic dermatitis, as well as any possible negative effects and overall disease control.

➤ Evaluate the Effectiveness, safety, and tolerability of Dupilumab compared to other biologic drugs in pediatric atopic dermatitis therapy, such as Tralokinumab or Omalizumab.

### LIMITATIONS

➤ The severity of atopic dermatitis in children significantly influenced the response to Dupilumab treatment, making it challenging to draw definitive conclusions.

➤ Dupilumab treatment's high cost and accessibility issues in certain healthcare settings caused hindrances in its widespread adoption and data availability in research studies.

### REFERENCES

- Albrecht, M., & Dittrich, A. (2015). Expression and function of histamine and its receptors in atopic dermatitis. *Molecular and cellular pediatrics*, 2, 1-8.
- Amber, T., & Tabassum, S. (2020). Cyclosporin in dermatology: A practical compendium. *Dermatologic Therapy*, 33(6), e13934.
- Anderson III, W. C., & Szefer, S. J. (2019). Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic? *Annals of Allergy, Asthma & Immunology*, 122(4), 367-372.
- Antti, A., Salava, A., Perälä, M., Pelkonen, A. S., Mäkelä, M. J., & Remitz, A. (2021). Are infants and toddlers with moderate-to-severe atopic dermatitis undertreated? Experiences of a Finnish tertiary care hospital. *Acta Dermato-Venereologica*, 101(1).
- Axon, E., Chalmers, J. R., Santer, M., Ridd, M. J., Lawton, S., Langan, S. M., Grindlay, D. J., Muller, I., Roberts, A., & Ahmed, A. (2021). Safety of topical corticosteroids in atopic eczema: an umbrella review. *BMJ open*, 11(7), e046476.
- Berna-Rico, E., Fiz-Benito, E., Busto-Leis, J. M., Servera-Negre, G., de Lucas-Laguna, R., & Feito-Rodriguez, M. (2023). Effectiveness and safety of dupilumab in children under 6 years of age with moderate-to-severe atopic dermatitis: a retrospective real-world study. *Dermatology*, 1-1.
- Berth-Jones, J., Damstra, R. J., Golsch, S., Livden, J. K., Van Hooteghem, O., Allegra, F., & Parker, C. A. (2003). Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. *Bmj*, 326(7403), 1367.
- Bohannon, M., Liu, M., Nadeau, P., Talton, J., Gibson, D., Datta, S., Schultz, G., Talton, J., & De Benedetto, A. (2020). Topical doxycycline monohydrate hydrogel 1% targeting proteases/PAR2 pathway is a novel therapeutic for atopic dermatitis. *Experimental dermatology*, 29(12), 1171-1175.
- Caffarelli, C., Giannetti, A., Gianni, G., & Ricci, G. (2023). Anti-inflammatory and biologic drugs for atopic dermatitis: a therapeutic approach in children and adolescents. *Frontiers in Medicine*, 10.
- Choi, C. W., Yang, B. R., Suh, D. I., Kim, M. S., Ohn, J., Hong, J. S., Lee, J., & Kim, K. H. (2020). Infection, antibiotic exposure and development of atopic dermatitis: A nationwide case-control study. *The*

- Journal of dermatology*, 47(7), 707-713.
- Chovatiya, R., & Silverberg, J. I. (2019). Pathophysiology of atopic dermatitis and psoriasis: implications for management in children. *Children*, 6(10), 108.
- Chu, A. W., Wong, M. M., Rayner, D. G., Guyatt, G. H., Martinez, J. P. D., Ceccacci, R., Zhao, I. X., McMullen, E., Srivastava, A., & Wang, J. (2023). Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. *Journal of Allergy and Clinical Immunology*, 152(6), 1470-1492.
- Class, I., Class, I., & Class, I. (2022). Systemic antibiotic prophylaxis for recurrent infective flares in children and adolescents with atopic dermatitis. *Ann Acad Med Singap*, 51(2), 113-114.
- Cork, M. J., Danby, S. G., Rossi, A. B., & Bansal, A. (2024). Dupilumab Treatment in Pediatric Patients Aged 6–11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review. *Drug Design, Development and Therapy*, 277-289.
- Coskey, R. J. (1978). Contact dermatitis due to clindamycin. *Archives of Dermatology*, 114(3), 446-446.
- Deleanu, D., & Nedelea, I. (2019). Biological therapies for atopic dermatitis: An update. *Experimental and therapeutic medicine*, 17(2), 1061-1067.
- Dhamija, S., Patel, R., Pol, S. A., Kulkarni, S., & Yamagar, N. (2024). Comparing Treatment Outcome of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray and Nasal Douching. *Journal of Clinical Otorhinolaryngology*, 6(1).
- Drucker, A., Eyerich, K., de Bruin-Weller, M., Thyssen, J. P., Spuls, P., Irvine, A., Girolomoni, G., Dhar, S., Flohr, C., & Murrell, D. (2018). Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. *British Journal of Dermatology*, 178(3), 768-775.
- Drug Trials Snapshots: DUPIXENT (2017). Food And Drug Administration.
- FDA. (2019). BLA Multi-Disciplinary review and Evaluation. Food and drug administration.
- Ferrucci, S. M., Tavecchio, S., Marzano, A. V., & Buffon, S. (2023). Emerging systemic treatments for atopic dermatitis. *Dermatology and Therapy*, 13(5), 1071-1081.
- Frazier, W., & Bhardwaj, N. (2020). Atopic dermatitis: diagnosis and treatment. *American family physician*, 101(10), 590-598.
- Grobe, W., Bieber, T., & Novak, N. (2019). Pathophysiology of atopic dermatitis. *JDDG: Journal der deutschen dermatologischen Gesellschaft*, 17(4), 433-440.
- Haeck, I. M., Rouwen, T. J., Timmer-de Mik, L., de Bruin-Weller, M. S., & Bruijnzeel-Koomen, C. A. (2011). Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. *Journal of the American Academy of Dermatology*, 64(2), 275-281.
- Harvey, J., Lax, S. J., Lowe, A., Santer, M., Lawton, S., Langan, S. M., Roberts, A., Stuart, B., Williams, H. C., & Thomas, K. S. (2023). The long-term safety of topical corticosteroids in atopic dermatitis: A systematic review. *Skin Health and Disease*, 3(5), e268.
- Hon, K. L. E., Chan, V. P., & Leung, A. K. (2021). Experimental drugs with the potential to treat atopic eczema. *Journal of experimental pharmacology*, 487-498.
- Hulme, J. (2023). Staphylococcus Infection: Relapsing Atopic Dermatitis and Microbial Restoration. *Antibiotics*, 12(2), 222.
- Kamal, M. A., Kovalenko, P., Kosloski, M. P., Srinivasan, K., Zhang, Y., Rajadhyaksha, M., Lai, C. H., Kanamaluru, V., Xu, C., & Sun, X. (2021). The posology of dupilumab in pediatric patients with atopic dermatitis. *Clinical Pharmacology & Therapeutics*, 110(5), 1318-1328.
- Kamphuis, E., Boesjes, C. M., Loman, L., Bakker, D. S., Poelheken, M., Zuithoff, N. P., Kamsteeg, M., Romeijn, G. L., van Wijk, F., & de Bruin-Weller, M. S. (2022). Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry. *Pediatric Allergy and Immunology*, 33(12), e13887.
- Kim, J., Kim, B. E., & Leung, D. Y. (2019). Pathophysiology of atopic dermatitis: Clinical implications. *Allergy and asthma proceedings*,
- Kraft, M., & Worm, M. (2017). Dupilumab in the treatment of moderate-to-severe atopic dermatitis. *Expert review of clinical immunology*, 13(4), 301-310.
- Lee, J. H., Yun, S.-J., Lee, J.-B., & Lee, S.-C. (2020). Therapeutic efficacy and safety of methotrexate in moderate-to-severe atopic dermatitis: a retrospective study of Korean patients at tertiary referral hospital. *Annals of Dermatology*, 32(5), 402.
- Li, Y., Jing, D., Huang, Y., Su, J., Li, J., Li, J., Tao, J., Shan, S., Wang, X., & Kang, X. (2021). Association of antibiotics use in preschool age with atopic and allergic skin diseases in young adulthood: a population-based retrospective cohort study. *BMJ open*, 11(9), e047768.
- Mandlik, D. S., & Mandlik, S. K. (2021). Atopic dermatitis: new insight into the etiology, pathogenesis, diagnosis and novel treatment strategies. *Immunopharmacology and immunotoxicology*, 43(2), 105-125.
- Martins, J. C., Martins, C., Aoki, V., Gois, A. F., Ishii, H. A., & da Silva, E. M. (2015). Topical tacrolimus for atopic dermatitis. *Cochrane Database of Systematic Reviews*(7).
- Megna, M., Napolitano, M., Patruno, C., Villani, A., Balato, A., Monfrecola, G., Ayala, F., & Balato, N. (2017). Systemic treatment of adult atopic dermatitis: a review. *Dermatology and Therapy*, 7, 1-23.
- Mehta, Y., & Fulmali, D. G. (2022). Relationship between atopic dermatitis and food allergy in children. *Cureus*, 14(12).
- Montes-Torres, A., Llamas-Velasco, M., Pérez-Plaza, A., Solano-López, G., & Sánchez-Pérez, J. (2015). Biological treatments in atopic dermatitis. *Journal of Clinical Medicine*, 4(4), 593-613.
- Mose, A. P., Usamah, A., & Svedman, C. (2022). Allergic contact dermatitis to topical clindamycin in a patient with hidradenitis suppurativa. *Acta Dermato-*

- Venerologica, 102.
- Mubanga, M., Lundholm, C., D'Onofrio, B. M., Stratmann, M., Hedman, A., & Almqvist, C. (2021). Association of early life exposure to antibiotics with risk of atopic dermatitis in Sweden. *JAMA Network open*, 4(4), e215245-e215245.
- Nakahara, T., Kido-Nakahara, M., Tsuji, G., & Furue, M. (2021). Basics and recent advances in the pathophysiology of atopic dermatitis. *The Journal of dermatology*, 48(2), 130-139.
- Napolitano, M., Fabbrocini, G., Neri, I., Stingeni, L., Boccaletti, V., Piccolo, V., Amoroso, G. F., Malara, G., De Pasquale, R., & Di Brizzi, E. V. (2022). Dupilumab treatment in children aged 6–11 years with atopic dermatitis: a multicentre, real-life study. *Pediatric Drugs*, 24(6), 671-678.
- Neri, L. (2015). Antibiotic therapy in the management of atopic dermatitis. *Giornale italiano di dermatologia e venerologia: organo ufficiale, Societa italiana di dermatologia e sifilografia*, 150(3), 321-325.
- Nicholas, M. N., Keown-Stoneman, C. D., Maguire, J. L., & Drucker, A. M. (2022). Association between atopic dermatitis and height, body mass index, and weight in children. *JAMA dermatology*, 158(1), 26-32.
- Ohsawa, Y., & Hirasawa, N. (2014). The role of histamine H1 and H4 receptors in atopic dermatitis: from basic research to clinical study. *Allergy International*, 63(4), 533-542.
- Paolino, A., Alexander, H., Broderick, C., & Flohr, C. (2023). Non-biologic systemic treatments for atopic dermatitis: current state of the art and future directions. *Clinical & Experimental Allergy*, 53(5), 495-510.
- Papp, K. A., Hong, C.-h., Lansang, M. P., Turchin, I., Adam, D. N., Beecker, J. R., Bissonnette, R., Gooderham, M. J., Jack, C., & Joseph, M. (2021). Practical management of patients with atopic dermatitis on dupilumab. *Dermatology and Therapy*, 11, 1805-1828.
- Phan, K., & Smith, S. D. (2020). Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis. *Journal of Dermatological Treatment*, 31(8), 810-814.
- Rajagopalan, M., Saraswat, A., Chandrashekar, B. S., Dhar, S., Dogra, S., Tahiliani, S., & Raj, P. (2022). Role of cyclosporine (CsA) in immuno-dermatological conditions. *Indian Dermatology Online Journal*, 13(5), 585-599.
- Rist, T., Parish, L., Capin, L., Sulica, V., Bushnell, W., & Cupo, M. (2002). A comparison of the efficacy and safety of mupirocin cream and cephalexin in the treatment of secondarily infected eczema. *Clinical and experimental dermatology*, 27(1), 14-20.
- Rusiñol, L., & Puig, L. (2024). Multi-Omics Approach to Improved Diagnosis and Treatment of Atopic Dermatitis and Psoriasis. *International Journal of Molecular Sciences*, 25(2), 1042.
- Schaper-Gerhardt, K., Rossbach, K., Nikolouli, E., Werfel, T., Gutzmer, R., & Mommert, S. (2020). The role of the histamine H4 receptor in atopic dermatitis and psoriasis. *British journal of pharmacology*, 177(3), 490-502.
- Shah, N., Alhusayen, R., Walsh, S., & Shear, N. H. (2018). Methotrexate in the treatment of moderate to severe atopic dermatitis: a retrospective study. *Journal of cutaneous medicine and surgery*, 22(5), 484-487.
- Soares, G. B., Hashimoto, T., & Yosipovitch, G. (2024). Atopic Dermatitis Itch: Scratching for an Explanation. *Journal of Investigative Dermatology*.
- Sonya Kahn, M., Rind, D., Chapman, R., Kumar, V., Kahn, S., & Carlson, J. (2018). Economic evaluation of dupilumab for moderate-to-severe atopic dermatitis: a cost-utility analysis. *J Drugs Dermatol*, 17(7), 750-756.
- Stacey, S. K., & McEleney, M. (2021). Topical corticosteroids: choice and application. *American family physician*, 103(6), 337-343.
- Study of Dupilumab. (2017). Clinical trials. gov.
- Subramanian, I., Singh, V. K., & Jere, A. (2018). Elucidating mechanistic insights into drug action for atopic dermatitis: a systems biology approach. *BMC dermatology*, 18, 1-12.
- Umar, B. U., Rahman, S., Dutta, S., Islam, T., Nusrat, N., Chowdhury, K., Ahmad, W. F. S. B. W., Haque, M., Umar, B. U. U., & Fakuradzi, W. F. S. W. A. (2022). Management of atopic dermatitis: the role of tacrolimus. *Cureus*, 14(8).
- Xu, X., van Galen, L. S., Koh, M. J. A., Bajpai, R., Thng, S., Yew, Y. W., Ho, V. P. Y., Alagappan, U., Järbrink, K. S. A., & Car, J. (2019). Factors influencing quality of life in children with atopic dermatitis and their caregivers: a cross-sectional study. *Scientific Reports*, 9(1), 15990.
- Zhou, S., Qi, F., Gong, Y., Zhang, J., & Zhu, B. (2021). Biological therapies for atopic dermatitis: a systematic review. *Dermatology*, 237(4), 542-552.